XNASNEOG
Market cap2.69bUSD
Dec 27, Last price
12.43USD
1D
0.00%
1Q
-25.17%
Jan 2017
-74.89%
Name
Neogen Corp
Chart & Performance
Profile
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | 2018‑05 | 2017‑05 | 2016‑05 | 2015‑05 | |
Income | ||||||||||
Revenues | 924,222 12.37% | 822,447 56.01% | 527,159 12.53% | |||||||
Cost of revenue | 865,559 | 784,932 | 468,541 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 58,663 | 37,515 | 58,618 | |||||||
NOPBT Margin | 6.35% | 4.56% | 11.12% | |||||||
Operating Taxes | (4,884) | 828 | 11,900 | |||||||
Tax Rate | 2.21% | 20.30% | ||||||||
NOPAT | 63,547 | 36,687 | 46,718 | |||||||
Net income | (9,421) -58.81% | (22,870) -147.34% | 48,307 -20.65% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 2,456 | 7,933 | ||||||||
BB yield | -0.09% | -0.28% | ||||||||
Debt | ||||||||||
Debt current | 7,548 | 1,440 | ||||||||
Long-term debt | 901,138 | 903,063 | 1,790 | |||||||
Deferred revenue | (353,427) | 17,011 | ||||||||
Other long-term liabilities | 351,677 | 27,065 | (8,099) | |||||||
Net debt | 737,521 | 692,101 | (368,739) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 35,264 | 41,028 | 68,038 | |||||||
CAPEX | (111,421) | (65,757) | (24,429) | |||||||
Cash from investing activities | (29,309) | 201,039 | (97,229) | |||||||
Cash from financing activities | 1,918 | (118,081) | 6,813 | |||||||
FCF | (109,723) | (83,976) | 25,294 | |||||||
Balance | ||||||||||
Cash | 170,936 | 245,569 | 381,051 | |||||||
Long term investments | 229 | (34,607) | (9,082) | |||||||
Excess cash | 124,954 | 169,840 | 345,611 | |||||||
Stockholders' equity | 560,257 | 566,389 | 577,390 | |||||||
Invested Capital | 4,277,104 | 3,885,693 | 551,777 | |||||||
ROIC | 1.56% | 1.65% | 8.95% | |||||||
ROCE | 1.33% | 0.85% | 6.41% | |||||||
EV | ||||||||||
Common stock shares outstanding | 216,482 | 188,881 | 108,020 | |||||||
Price | 13.15 -24.81% | 17.49 -33.90% | 26.46 -42.67% | |||||||
Market cap | 2,846,737 -13.83% | 3,303,529 15.58% | 2,858,209 -42.18% | |||||||
EV | 3,584,258 | 3,995,630 | 2,489,470 | |||||||
EBITDA | 179,890 | 125,892 | 82,312 | |||||||
EV/EBITDA | 19.92 | 31.74 | 30.24 | |||||||
Interest | 73,394 | 55,961 | 1,267 | |||||||
Interest/NOPBT | 125.11% | 149.17% | 2.16% |